PRADAXA (DABIGATRAN EXTILATE) is promoted as a progressive and revolutionary blood thinner that is leading the charge for a new generation of anti-coagulants. It has only been approved in the U.S., as of March 2012, for use in patients with non-valvular AFib or Atrial Fibrillation. It was denied use for other indications in the U.S., by the FDA, despite uses for other purposes in other countries.

“PRADAXA is progress” has become the marketing mantra heard on TV commercials and claims in print ads. This slogan communicates a chemical superiority in comparison to other and older blood thinners. It almost implies that they are outdated by the new promise of PRADAXA. The target of this slogan is WARFARIN or COUMADIN the staple of anti-coagulants for over 1/2 of a century. It is often likened to ‘rat poison’ because of its origin and the fact that an antidote exits to reverse blood thinning effects it creates. WARFARIN and COUMADIN carry the risk of bleeding or hemorrhaging. However, it is regularly monitored and dosed according to each patient and their tolerance. It now has a track history and is reversed by certain protocol, including Vitamin K, and nearly 1/2 a century of experience. Yet, “PRADAXA is progress” claims BOEHRINGER INGELHEIM through mass media marketing and social media promotions.

Is PRADAXA progress? No Antidote - No Quick Reversal.

PRADAXA has no known, or widely available antidote or quick reversal agent. This means that any user is at increased risk of uncontrolled bleeding events with little to impede their literally bleeding to death if they are not immediately treated regardless of their age. Even then, because there is no quick reversal agent, uniform protocol or antidote, addressing an emergency involving PRADAXA CASES can have dire consequences. Is this progress? If so at what expense and how many patients would knowing risk their life if they knew there is no antidote or reversal agent? 

As lawsuits begin to address the warnings provided to consumers and prescribers the communication of this risk, and others, will be addressed.  PRADAXA CASES reported internationally indicate that some patients may have paid with their life before red flags, increased warnings and safety alerts were issued in November 2011 of the serious risks posed by PRADAXA.

PRADAXA CASES is sponsored by Gabriel F. Zambrano, P.A.. Gabriel F. Zambrano, P.A., is actively investigating PRADAXA CASES involving serious personal injuries, hemorrhaging, disabilities and death from PRADAXA (DABIGATRAN EXTILATE). You can request a FREE PRADAXA CASE EVALUATION by using the contact form below.

PRADAXA® CASES - AFIB INDICATION.